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Over the last decades, numerous papers have appeared—and still are appearing—that describe
concentrations in tissues in an effort to predict the efﬁcacy of an antimicrobial agent based on these
concentrations and MICs for microorganisms. A common method is to use measurements of concen-
trations in tissue homogenates, comparing these with values derived from the corresponding blood
samples and on that basis draw conclusions with respect to the potential clinical use of the drug. This
approach is not justiﬁable for a number of reasons that includes both pharmacokinetic as well as phar-
macodynamic causes. This way of presenting data with the derived conclusions is often misleading
and may ultimately be harmful in patient care.
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Introduction
Over the last decades, studies have been performed that describe
whole tissue concentrations of antimicrobials derived from
homogenates. In a number of these the authors subsequently use
the results to draw conclusions towards the activity and efﬁcacy
of the drug.
1–6Measuring concentrations in tissue homogenates,
comparing them with the corresponding blood samples and
recommending the drug for clinical use based on such pharma-
cokinetic data, is not justiﬁable as has been shown more then 25
years ago.
7 We consider this way of presenting data with its
derived conclusions misleading and, because erroneous con-
clusions may be drawn with respect to the activity of the drug,
also potentially harmful in patient care.
In the following, we brieﬂy provide the scientiﬁc basis for
our arguments and show a number of examples to underscore
our point of view based on current knowledge on concentrations
at the site of infection.
What do tissue concentrations represent?
Whole tissue concentrations are usually obtained by grinding up
(homogenizing) or lysing tissue and subsequently determining
the concentration of the antibiotic in the tissue homogenate.
However, this does not take into account the fact that tissues are
made of distinct compartments (interstitial ﬂuid, cells, and
within cells the various subcellular organelles) in which the
drug is not necessarily distributed in a homogeneous fashion.
Moreover, measurements in tissue homogenates do not give any
information on whether the drug is actually available for
activity. Thus, when whole tissue concentrations are determined
by measuring the overall concentration in the tissue homogenate,
the concentrations found are not informative with respect to the
(active) concentration of the antimicrobial at the site of infec-
tion.
7–9Since most bacterial infections are located in the extra-
cellular compartment, those concentrations are of primary
interest. If a compound is distributed mainly extracellularly,
such as b-lactams and aminoglycosides, grinding up the tissue
means dilution of the drug by mixing intracellular and extra-
cellular ﬂuids, resulting in underestimation of its concentrations
at the site of infection. Conversely, if drugs are accumulated by
cells (such as ﬂuoroquinolones or macrolides), assay of total
tissue levels will lead to gross overestimation of the extracellular
concentration. The opposite is true for intracellular infections.
Pharmacokinetic relationships between serum and
tissue concentrations
After administration, an antibiotic (as any drug) becomes distribu-
ted into various compartments in the body. The pharmacokinetics
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compartment model, and the amount of drug transferred between
compartments is described by intercompartmental clearance. The
equilibrium between the compartments does not occur instan-
taneously and the shape of the concentration–time curve in either
compartment can therefore be markedly different.
10 The reasons
for the differences are delayed steady-state, time-lags to and from
other compartments as documented in numerous studies, including
those where concentrations have been determined in speciﬁc com-
partments.
8,11–15 Depending on the time a whole tissue sample is
taken (in most situations only once), any value of a ratio of tissue
concentration versus serum concentration can be obtained.
Figure 1 and Table 1 illustrate this by showing the concentration–
time curves in serum and two tissue compartments and the ratio of
serum to tissue concentration in these two compartments. To cir-
cumvent the problem, multiple samples would have to be taken in
a steady-state situation using an appropriate technique in a single
patient, which is often unpractical and even ethically questionable.
Alternatively, samples could be taken at multiple time-points from
different individuals, in both cases directly from the speciﬁed
compartment, but this would introduce a large possibility for
errors due to interindividual variabilities.
Pharmacokinetic/pharmacodynamic relationships
Pharmacokinetic/pharmacodynamic relationships have been
described for a number of drugs, using serum concentrations as
a surrogate for the concentrations at the actual site of infection.
These relationships show a marked consistency, and the pharma-
codynamic index values (such as AUC/MIC) that result in a
certain effect have been determined for most classes of anti-
biotics.
16,17 The pharmacokinetic/pharmacodynamic index
values are derived from concentrations measured in serum over
time and it is inappropriate to infer similar effects from tissue
concentrations or local concentrations. Statements such as ‘con-
centrations in tissue x h after dosing are much higher than the
MICs for common pathogens
2,4 that cause disease’ are
meaningless.
The concentrations may have been lower or higher in relation
to the serum concentrations, and the values of the denominator
are therefore incorrect, while the drug exposure over time is not
included either. If inferences are drawn from local concen-
trations, the concentration–effect relationships at the actual
infection site should be used and these are usually unknown.
When are tissue concentrations of value?
It is very difﬁcult to determine the concentration of a drug at the
site of the infection and/or at the receptor site. This is one of the
reasons that the surrogate values in serum are being used.
Although the results of using these surrogates are remarkably
consistent, aberrations do occur, for instance unexpected failure
or success of treatment. In those cases, concentrations at the site
of infection, using a validated method, could certainly be of
value. Measurements in speciﬁc compartments (such as epi-
thelial lining ﬂuid and CSF) or determining free concentrations
in interstitial ﬂuid by microdialysis contribute to our understand-
ing of concentrations at the site of infection.
18 It should be
borne in mind, however, that all these methods may suffer from
methodological problems that are not always immediately appar-
ent. Finally, whole tissue concentrations can be of value in
Figure 1. Schematic ﬁgure showing the concentration–time course in three locations: serum, extracellular and intracellular. The six arrows indicate sample
time-points in each of the three locations; the concentrations were used to determine the ratios in Table 1.
Table 1. Extracellular and intracellular concentration/serum
concentration ratios as a function of sample drawing time
Hours post
ﬁrst dose
Extracellular concentration/
serum concentration ratio
Intracellular concentration/
serum concentration ratio
0.85 1.00 0.15
2 1.58 0.45
3.8 1.60 1.00
6 1.40 1.87
8 1.59 0.78
32 1.57 1.21
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236initial studies during drug development to determine the overall
distribution of a drug.
Conclusions
We conclude that, comparable to the expressions used by both
the European Medicines Agency
19 as well as the ASM,
20 the
use and determination of tissue concentrations derived from
homogenates to draw direct conclusions on drug activity are
unwarranted and/or unreliable.
21,22 Statements that infer activity
of the drug based on concentrations measured in relation to the
susceptibility (MIC) of the agent should be avoided.
Alternatively, measurements of concentrations in speciﬁed com-
partments may yield information that is much needed to under-
stand the efﬁcacy of an antimicrobial but should be
supplemented with effective measures of activity and/or clinical
evidence. In that respect, the use of unbound serum concen-
trations has proved to be useful as a surrogate correlate.
23 Using
concentrations in tissue-homogenates alone to determine
exposure–response relationships and drawing conclusions with
respect to clinical use are unjustiﬁed and may ultimately be
harmful to patients.
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